

## SEQUENCE LISTING

## RECEIVED

JUN 2 8 2002

TECH CENTER 1600/2900

## <110> PHOGEN, LIMITED O'Hare, Peter Francis Joseph Normand, Nadia Michelle

- <120> DELIVERY OF SUBSTANCES TO CELLS
- <130> 5759-54451
- <140> US 09/522,278
- <141> 2000-03-09
- <150> GB 9930499.0
- <151> 1999-12-24
- <150> GB 9905444.7
- <151> 1999-03-10
- <160> 12
- <170> PatentIn version 3.1
- <210> 1
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> ·1
- ccccaccac ttcccctctc

20

- <210> 2
- <211> 40
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> 2
- tcctcgccct tgctcaccat ggtggcgacc ggtggatccc

40

- <210> 3
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> 3
- cccttgctca ccatggtggc

20

<210> 4

<211> <212> <213>	DNA Artificial Sequence										
<220> <223>	Oligonucleotide primer										
<400> accatg	4 gtgg cgaccggtgg atccc	25									
<210><211><211><212><213>	20 DNA										
<220> <223>	Oligonucleotide primer										
<400>	5 ctca ccatggtggc	20									
<210><211><211><212><213>	7.										
<220> <223>	Oligonucleotide primer										
<400>	6 ccac ttcccctctc	20									
<210><211><211><212><213>	7 131 DNA Artificial Sequence										
<220> <223>	Oligonucleotide primer										
	7 atgg ggcaggtggg acggcagctc gccatcatcg gggacgacat caaccgacgc	60									
tatcgg	gate eegatagegt eggttgatgt egteeeegat gatggegage tgeegteeea	120									
cctgcc	ccat g	131									
<210><211><211><212><213>	8 36 RNA Artificial Sequence										
<220> <223>	Oligonucleotide primer										
<400>	8										

guui	iucc	cug a	auga	ggcc	ga a	aggc	cgaa	a uu	cuce								36
<210 <210 <210 <210	L> 2>	9 20 DNA Arti:	fici	al S	eque	nce											
<220 <223		Oligonucleotide primer															
<400> 9 ccccaccac ttcccctctc												20					
CCCC	Cac	Cac			LC												20
<210 <211 <212 <213	L> 2>	10 17 DNA Artificial Sequence															
<220 <223		Oligonucleotide primer															
<400 cca		10 gac q	ggcg	ccc													17
<210 <211 <212 <213	l> 2>																
<220 <223		Oligo	onuc:	leot:	ide p	orime	er							•			
<400		11 tgt (	gacai	tgcai	tt											•	20
<210 <211 <212 <213	L> 2>	12 301 PRT herpe	es s:	imple	ex vi	irus	1										
<400	)>	12															
Met 1	Thr	Ser	Arg	Arg 5	Ser	Val	Lys	Ser	Gly 10	Pro	Arg	Glu	Val	Pro 15	Arg		
Asp	Glu	Tyr	Glu 20	Asp	Leu	Tyr	Tyr	Thr 25	Pro	Ser	Ser	Gly	Met 30	Ala	Ser		
Pro	Asp	Ser 35	Pro	Pro	Asp	Thr	Ser 40	Arg	Arg	Gly	Ala	Leu 45	Gln	Thr	Arg		
Ser	Arg 50	Gln	Arg	Gly	Glu	Val 55	Arg	Phe	Val	Gln	Tyr 60	Asp	Glu	Ser	Asp		

Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu 65 70 75 80

Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro 85 90 95

Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly 100 105 110

Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala
115 120 125

Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys
130 . 135 140

Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr 145 150 155 160

Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu 165 170 175

His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg
180 185 190

Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu 195 200 205

Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser 210 215 220

Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr 225 230 235 240

Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn 245 250 255

Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala 260 265 270

Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala 275 280 285

Pro Ala Arg Ser Ala Ser Arg Pro Arg Pro Val Glu 290 295 300 SEQUENCE LISTING

## RECEIVED

JUN 2 8 2002

**TECH CENTER 1600/2900** 

<110> PHOGEN, LIMITED O'Hare, Peter Francis Joseph Normand, Nadia Michelle

- <120> DELIVERY OF SUBSTANCES TO CELLS
- <130> 5759-54451
- <140> US 09/522,278
- <141> 2000-03-09
- <150> GB 9930499.0
- <151> 1999-12-24
- <150> GB 9905444.7
- <151> 1999-03-10
- <160> 12
- <170> PatentIn version 3.1
- <210> 1
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> 1
- ccccaccac ttcccctctc
- <210> 2
- <211> 40
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> 2
- tcctcgccct tgctcaccat ggtggcgacc ggtggatccc
- <210> 3
- <211> 20
- <212> DNA
- <213> Artificial Sequence
- <220>
- <223> Oligonucleotide primer
- <400> 3
- cccttgctca ccatggtggc

24

20

40

20

<210>	4	
<211>	25	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Oligonucleotide primer	
<400>	4	
accatg	gtgg cgaccggtgg atccc	25
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
<223>	Oligonucleotide primer	
<400>	5	
cccttg	ctca ccatggtggc	20
-210-		
<210>		
<211>		
<212>		
<213>	Artificial Sequence	
<220>		
	Oligonucleotide primer	
(2237	Oligonacicotiae plimei	
<400>	6	
	ccac ttcccctctc	20
<210>	7	
<211>	131	
<212>	DNA	
<213>	Artificial Sequence	
<220>		
<223>	Oligonucleotide primer	
<400>	7	
gatccta	atgg ggcaggtggg acggcagctc gccatcatcg gggacgacat caaccgacgc	60
tatcggg	gatc cegatagegt eggttgatgt egteceegat gatggegage tgeegteeea	120
cctgcc	ccat g	131
<210>	8	
<2115	36	

<211> 36 <212> RNA

27

```
<213> Artificial Sequence
<220>
<223> Oligonucleotide primer
<400> 8
guuuucccug augaggccga aaggccgaaa uucucc
                                                                      36
<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide primer
<400> 9
                                                                      20
ccccaccac ttcccctctc
<210> 10
<211> 17
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide primer
<400> 10
                                                                      17
ccacaccgac ggcgccc
<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> Oligonucleotide primer
<400> 11
                                                                     20
tcccgcctgt gacatgcatt
<210> 12
<211> 301
<212> PRT
<213> herpes simplex virus 1
<400> 12
Met Thr Ser Arg Arg Ser Val Lys Ser Gly Pro Arg Glu Val Pro Arg
1
               5
                                   10
                                                       15
```

Asp Glu Tyr Glu Asp Leu Tyr Tyr Thr Pro Ser Ser Gly Met Ala Ser



20 25 30

Pro Asp Ser Pro Pro Asp Thr Ser Arg Arg Gly Ala Leu Gln Thr Arg 35 40 45

Ser Arg Gln Arg Gly Glu Val Arg Phe Val Gln Tyr Asp Glu Ser Asp 50 55 60

Tyr Ala Leu Tyr Gly Gly Ser Ser Ser Glu Asp Asp Glu His Pro Glu 65 70 75 80

Val Pro Arg Thr Arg Arg Pro Val Ser Gly Ala Val Leu Ser Gly Pro 85 90 95

Gly Pro Ala Arg Ala Pro Pro Pro Pro Ala Gly Ser Gly Gly Ala Gly
100 105 110

Arg Thr Pro Thr Thr Ala Pro Arg Ala Pro Arg Thr Gln Arg Val Ala
115 120 125

Thr Lys Ala Pro Ala Ala Pro Ala Ala Glu Thr Thr Arg Gly Arg Lys 130 135 140

Ser Ala Gln Pro Glu Ser Ala Ala Leu Pro Asp Ala Pro Ala Ser Thr 145 150 155 160

Ala Pro Thr Arg Ser Lys Thr Pro Ala Gln Gly Leu Ala Arg Lys Leu 165 170 175

His Phe Ser Thr Ala Pro Pro Asn Pro Asp Ala Pro Trp Thr Pro Arg 180 185 190

Val Ala Gly Phe Asn Lys Arg Val Phe Cys Ala Ala Val Gly Arg Leu 195 200 205

Ala Ala Met His Ala Arg Met Ala Ala Val Gln Leu Trp Asp Met Ser 210 215 220

Arg Pro Arg Thr Asp Glu Asp Leu Asn Glu Leu Leu Gly Ile Thr Thr 225 230 235 240

Ile Arg Val Thr Val Cys Glu Gly Lys Asn Leu Leu Gln Arg Ala Asn 245 250 255



Glu Leu Val Asn Pro Asp Val Val Gln Asp Val Asp Ala Ala Thr Ala 260 265 270

Thr Arg Gly Arg Ser Ala Ala Ser Arg Pro Thr Glu Arg Pro Arg Ala 275 280 285

Pro Ala Arg Ser Ala Ser Arg Pro Arg Arg Pro Val Glu 290 295 300